The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...

US guidelines recommend the PRECISE-DAPT score to assess bleeding risk. The European approach uses this or the ARC-HBR score, ...

The following is a summary of “Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet ...

C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...

Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...

The cyclooxygenase-2 inhibitors are not antiplatelet drugs. [2] In 1998 only one drug in this class was available, a monoclonal antibody (abciximab) directed against the fibrinogen receptor on the ...

"The $7.3 billion is the difference between what they are reimbursing themselves and what it is estimated to cost them to acquire the drug," an FTC spokesperson told reporters in a press briefing ...

Drugmakers raised the list prices on 575 name-brand drugs in just the first two days of the new year, according to drug price research firm 46brooklyn. Drugs for diabetes, HIV, cancer saw price ...

Heart disease, one of the leading causes of death worldwide, has long posed challenges in terms of both treatment and prevention. However, with recent advances in pharmaceutical medicine, managing ...

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

This meta-analysis compared the efficacy and safety of low-dose versus standard-dose antiplatelet drugs in stroke patients. Ten RCTs were included, of which 2 (18.18%) were published after 2020, ...

Non-steroid anti-inflammatory drugs were not associated with CRNMB (OR 1.0, 95% CI 0.25-4.1) or major bleedings (OR 0.72, 95% CI 0.14 -3.6). Use of antiplatelet therapy was not associated with CRNMB ...